MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    How Does Mild Cognitive Impairment in Parkinson’s Disease Affect Communication Abilities?

    F. Rodriguez-Porcel, T. Turner (Charleston, USA)

    Objective: We explored differences in communication abilities in people with Parkinson’s disease (PwP) with mild cognitive impairment (MCI) (PwP-MCI) and those with normal cognition (PwP-CN).…
  • 2024 International Congress

    Subtyping Parkinson’s Disease Mild Cognitive Impairment (PD-MCI) by Cholinergic Degeneration

    A. Negida, H. Vohra, H. Nawaz, M. Barrett (Henrico, USA)

    Objective: This study aims to investigate whether PD-MCI patients exhibiting cholinergic degeneration, evidenced by reduced Ch4 grey matter density (GMD) on brain MRIs, constitute a…
  • 2024 International Congress

    Personality of Parkinson’s disease patients may influence the development and evolution of non-motor fluctuations

    M. Boussac, F. Faggianelli, E. Harroch, A. Eusebio, M. Fabbri, F. Ory-Magne, E. Descamps, O. Rascol, C. Laurencin, AR. Marques, M. Anheim, B. Giordana, L. Hopes, C. Moreau, AS. Rolland, D. Devos, D. Maltete, S. Ansquer, E. Hainque, S. Drapier, JP. Brandel, T. Rouaud, D. Guehl, B. Jarraya, M. Tir, T. Witjas, JP. Azulay, C. Brefel-Courbon (Toulouse, France)

    Objective: to evaluate the impact of personality on non-motor fluctuations (NMFs) in Parkinson’s disease (PD) and on NMFs evolution after dopaminergic treatments or deep brain…
  • 2024 International Congress

    Changes in slow-wave sleep characteristics in Parkinson’s disease patients with depression

    C. Mao, J. Hu, Y. Wang, X. Cheng, J. Liu, F. Wang, C. Liu (Suzhou, China)

    Objective: This study used polysomnography (PSG) to examine the relationship between depression in PD and sleep characteristics, particularly (SWA). Background: Depression and sleep disturbance is…
  • 2024 International Congress

    Comparison of Age, Cognitive, Autonomic, and Motor Testing between Serotonergic vs Idiopathic REM-Sleep Behavior Disorder

    M. Berns, N. Reddy, H. Olson, R. Berns, M. Howell (Minneapolis, USA)

    Objective: To compare the age, cognitive, autonomic, and motor function of REM-Sleep Behavior Disorder (RBD) patients amongst those who believe their symptoms were triggered by…
  • 2024 International Congress

    Prevalence of Non-Motor Symptoms in Patients with Parkinson Disease in a Tertiary Hospital in Santiago, Chile.

    M. Sánchez, V. Rosado, C. Montalva, P. Salles, J. Fuentes, P. Chaná (Santiago, Chile)

    Objective: Objective:Determine the prevalence of NMS in patients with Parkinson disease attending the Hospital San Juan de Dios Neurology Clinic. Background: Background:Parkinson disease (PD) is…
  • 2024 International Congress

    Interim Report of Quality of Life Outcomes After Deep Brain Stimulation for Parkinson’s Disease from a Large Global Real-World Study

    A. Gharabaghi, L. Lopez, A. Schnitzler, S. Chen, L. Himes, M. Frassica, D. Nanduri, S. Groppa (Tuebingen, Germany)

    Objective: To summarize quality of life outcomes after 2 years of deep brain stimulation (DBS) for Parkinson’s disease (PD). Background: DBS improves motor fluctuations associated…
  • 2024 International Congress

    Transcranial Magnetic Stimulation of Median Prefrontal Cortex Improves Orthostatic Hypotension in Parkinson’s Disease

    S. Antipenko, A. Frohlich, M. Sklerov (Chapel Hill, USA)

    Objective: To evaluate transcranial magnetic stimulation (TMS) as a potential therapeutic tool for treatment of orthostatic hypotension (OH) in Parkinson’s disease (PD). Background: Autonomic dysfunction,…
  • 2024 International Congress

    Dopamine Dysregulation in Parkinson’s Disease and Substance Use: Therapeutic Use and Compulsive Behaviors Thin Line

    J. Hall, R. Islam, D. Nolasco, B. Carr (GAINESVILLE, USA)

    Objective: Parkinson's Disease (PD) inherently disrupts dopaminergic transmission, primarily within the nigrostriatal pathway, necessitating dopaminergic therapies. However, these therapies can lead to Dopamine Dysregulation Syndrome…
  • 2024 International Congress

    Safety of Pimavanserin for Parkinson’s Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies

    A. Berrio, L. Chrones, V. Abler, R. Hauser (San Diego, USA)

    Objective: To summarize the sleep and sedation-related safety and tolerability of pimavanserin for the treatment of Parkinson’s disease psychosis (PDP). Background: Pimavanserin, a 5-HT2A receptor…
  • « Previous Page
  • 1
  • …
  • 86
  • 87
  • 88
  • 89
  • 90
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Advanced Search
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley